S&P 500   4,136.53 (-0.21%)
DOW   32,806.90 (+0.01%)
QQQ   319.42 (-0.72%)
AAPL   164.60 (-0.45%)
MSFT   279.91 (-1.06%)
META   170.64 (+2.11%)
GOOGL   117.28 (-0.16%)
AMZN   138.75 (-1.46%)
TSLA   872.00 (+0.87%)
NVDA   174.17 (-8.28%)
NIO   20.22 (+0.00%)
BABA   90.56 (-2.16%)
AMD   99.71 (-2.54%)
MU   61.42 (-1.67%)
T   18.08 (-1.47%)
CGC   3.17 (+17.41%)
GE   75.50 (+1.53%)
F   15.82 (+3.40%)
DIS   109.13 (+2.34%)
AMC   24.29 (+9.51%)
PYPL   96.04 (+0.76%)
PFE   49.20 (-0.14%)
NFLX   233.69 (+3.05%)
S&P 500   4,136.53 (-0.21%)
DOW   32,806.90 (+0.01%)
QQQ   319.42 (-0.72%)
AAPL   164.60 (-0.45%)
MSFT   279.91 (-1.06%)
META   170.64 (+2.11%)
GOOGL   117.28 (-0.16%)
AMZN   138.75 (-1.46%)
TSLA   872.00 (+0.87%)
NVDA   174.17 (-8.28%)
NIO   20.22 (+0.00%)
BABA   90.56 (-2.16%)
AMD   99.71 (-2.54%)
MU   61.42 (-1.67%)
T   18.08 (-1.47%)
CGC   3.17 (+17.41%)
GE   75.50 (+1.53%)
F   15.82 (+3.40%)
DIS   109.13 (+2.34%)
AMC   24.29 (+9.51%)
PYPL   96.04 (+0.76%)
PFE   49.20 (-0.14%)
NFLX   233.69 (+3.05%)
S&P 500   4,136.53 (-0.21%)
DOW   32,806.90 (+0.01%)
QQQ   319.42 (-0.72%)
AAPL   164.60 (-0.45%)
MSFT   279.91 (-1.06%)
META   170.64 (+2.11%)
GOOGL   117.28 (-0.16%)
AMZN   138.75 (-1.46%)
TSLA   872.00 (+0.87%)
NVDA   174.17 (-8.28%)
NIO   20.22 (+0.00%)
BABA   90.56 (-2.16%)
AMD   99.71 (-2.54%)
MU   61.42 (-1.67%)
T   18.08 (-1.47%)
CGC   3.17 (+17.41%)
GE   75.50 (+1.53%)
F   15.82 (+3.40%)
DIS   109.13 (+2.34%)
AMC   24.29 (+9.51%)
PYPL   96.04 (+0.76%)
PFE   49.20 (-0.14%)
NFLX   233.69 (+3.05%)
S&P 500   4,136.53 (-0.21%)
DOW   32,806.90 (+0.01%)
QQQ   319.42 (-0.72%)
AAPL   164.60 (-0.45%)
MSFT   279.91 (-1.06%)
META   170.64 (+2.11%)
GOOGL   117.28 (-0.16%)
AMZN   138.75 (-1.46%)
TSLA   872.00 (+0.87%)
NVDA   174.17 (-8.28%)
NIO   20.22 (+0.00%)
BABA   90.56 (-2.16%)
AMD   99.71 (-2.54%)
MU   61.42 (-1.67%)
T   18.08 (-1.47%)
CGC   3.17 (+17.41%)
GE   75.50 (+1.53%)
F   15.82 (+3.40%)
DIS   109.13 (+2.34%)
AMC   24.29 (+9.51%)
PYPL   96.04 (+0.76%)
PFE   49.20 (-0.14%)
NFLX   233.69 (+3.05%)
NASDAQ:VCNX

Vaccinex - VCNX Stock Forecast, Price & News

Notice: Trading of Vaccinex halted at 11:01 AM EST due to "LULD pause".
$1.06
+0.03 (+2.91%)
(As of 08/8/2022 02:09 PM ET)
Add
Compare
Today's Range
$1.01
$1.49
50-Day Range
$1.01
$1.35
52-Week Range
$0.90
$2.60
Volume
45,438 shs
Average Volume
596,004 shs
Market Capitalization
$45.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Vaccinex MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Vaccinex in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

1101st out of 1,293 stocks

Pharmaceutical Preparations Industry

525th out of 619 stocks

VCNX stock logo

About Vaccinex (NASDAQ:VCNX) Stock

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Vaccinex Price Performance

Shares of Vaccinex stock remained flat at $1.03 during trading on Monday. The company had a trading volume of 45,135 shares, compared to its average volume of 596,004. Vaccinex has a twelve month low of $0.90 and a twelve month high of $2.60. The company has a quick ratio of 10.00, a current ratio of 10.00 and a debt-to-equity ratio of 0.01. The stock has a market cap of $43.94 million, a price-to-earnings ratio of -2.00 and a beta of 0.99. The business's fifty day simple moving average is $1.13 and its 200-day simple moving average is $1.25.

Vaccinex (NASDAQ:VCNX - Get Rating) last released its earnings results on Monday, May 16th. The company reported ($0.12) earnings per share (EPS) for the quarter.

Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

VCNX Stock News Headlines

See More Headlines
Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

VCNX Company Calendar

Last Earnings
5/16/2022
Today
8/08/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCNX
Employees
39
Year Founded
N/A

Profitability

Net Income
$-22,380,000.00
Pretax Margin
-40,802.00%

Debt

Sales & Book Value

Annual Sales
$900,000.00
Book Value
$0.24 per share

Miscellaneous

Free Float
22,356,000
Market Cap
$45.22 million
Optionable
Not Optionable
Beta
0.99

Key Executives

  • Dr. Maurice Zauderer Ph.D. (Age 76)
    Co-Founder, CEO, Pres & Director
    Comp: $374.9k
  • Mr. Scott E. Royer C.F.A. (Age 48)
    M.B.A., Chief Financial Officer
    Comp: $242.15k
  • Dr. Ernest S. Smith Ph.D. (Age 50)
    Sr. VP of Research & Chief Scientific Officer
    Comp: $264.74k
  • Dr. Deepak M. Sahasrabudhe
    Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor
  • Dr. Elizabeth E. Evans Ph.D. (Age 49)
    COO and Sr. VP of Discovery & Translational Medicine
  • Dr. John E. Leonard Ph.D. (Age 75)
    Sr. VP of Devel.













VCNX Stock - Frequently Asked Questions

How has Vaccinex's stock performed in 2022?

Vaccinex's stock was trading at $1.04 on January 1st, 2022. Since then, VCNX stock has increased by 14.4% and is now trading at $1.19.
View the best growth stocks for 2022 here
.

Are investors shorting Vaccinex?

Vaccinex saw a decline in short interest in the month of July. As of July 15th, there was short interest totaling 280,500 shares, a decline of 43.5% from the June 30th total of 496,500 shares. Based on an average daily volume of 95,700 shares, the short-interest ratio is presently 2.9 days. Approximately 1.3% of the company's stock are sold short.
View Vaccinex's Short Interest
.

When is Vaccinex's next earnings date?

Vaccinex is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our VCNX earnings forecast
.

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) released its quarterly earnings results on Monday, May, 16th. The company reported ($0.12) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

When did Vaccinex IPO?

(VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

What is Vaccinex's stock symbol?

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

How do I buy shares of Vaccinex?

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaccinex's stock price today?

One share of VCNX stock can currently be purchased for approximately $1.19.

How much money does Vaccinex make?

Vaccinex (NASDAQ:VCNX) has a market capitalization of $50.77 million and generates $900,000.00 in revenue each year. The company earns $-22,380,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How many employees does Vaccinex have?

Vaccinex employs 39 workers across the globe.

How can I contact Vaccinex?

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The official website for the company is www.vaccinex.com. The company can be reached via phone at (585) 271-2700, via email at mrice@lifesciadvisors.com, or via fax at 585-271-2765.

This page (NASDAQ:VCNX) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.